Abstract. PSM-E is a newly discovered alternatively spliced variant of prostate-specific membrane antigen (PSMA). In the current study, its role on the proliferation, invasiveness and migration in prostate cancer cell lines was analyzed. PSM-E and PSMA (as a comparison) eukaryotic expression vectors pcDNA3.0/PSM-E and pcDNA3.0/PSMA were constructed, validated by RT-PCR and Western blotting, and PSMA/PSM-E overexpression PC-3 cell models were built. Gene interference was used to block PSMA and the expression of its splice variants in LNCaP cells. Three shRNA fragments were synthesized against PSMA, cloned into the vector pSilencer 2.1-U6-neo, their interference effect was evaluated by RT-PCR and Western blotting, and pSilencer 2.1-U6-neo-shRNA3 (named p-shRNA3) was chosen in further analyses. Growth curves were drawn to observe the proliferation change, which showed that PSM-E had the potential to suppress proliferation (P<0.05), but no significant change was observed in PSMA/PC-3 cells and in PSMA/PSM-E interfering LNCaP cells (P>0.05). Cross-river test showed that the migration speeds of PSM-E/PC-3 and PSMA/PC-3 were both significantly slower than the vector negative control, and faster in p-shRNA3 interfering LNCaP cells compared with its vector negative control (P<0.05), and no significant difference existed between PSM-E/PC-3 and PSMA/PC-3 (P>0.05). Transwell assay showed that the invasive cells of both PSMA/PC-3 and PSM-E/PC-3 were fewer compared to the vector negative control (P<0.05), and the invasive suppression effect of PSM-E was weaker than PSMA (P<0.05), and accordingly, invasiveness of interfering LNCaP cells was enhanced compared with the vector negative control (P<0.05). These results showed that PSM-E could suppress proliferation, migration and invasiveness of prostate cancer cells. Its suppression effect on cell proliferation is stronger compared to PSMA and the suppression effect on invasiveness is weaker than that of PSMA.
Introduction
Prostate cancer (PCa) is one of the most common malignant tumors and is the second leading cause of mortality from cancer among males in Europe and America (1) . Its incidence has increased worldwide in recent years. Because the clinical symptoms of PCa are not always obvious, many patients were found to have metastasis by the time of diagnosis (2) . Therefore, it is very important to explore the biological behavior of its developing process.
Prostate-specific membrane antigen (PSMA) is a type Ⅱ transmembrane glycoprotein whose gene maps to chromosome 11p11-11p12, and is expressed on the surface of both normal and PCa cells (3) (4) (5) (6) (7) (8) . It consists of 750 amino acids and has a molecular weight of 100 kDa after glycosylation. It has two important enzymatic functions, namely, folate hydrolase and NAALADase (3) (4) (5) (6) (7) . Its expression in prostate cells is up to 50-fold higher than in other expressing tissues, such as kidney, bladder, brain, liver, and intestine (9, 10) . Importantly, PSMA is overexpressed in most PCa tissues, and also highly expressed in the neovasculature of a variety of solid tumors (11) (12) (13) , indicating that PSMA may correlate to cancer progression. Due to its high tissue specificity and pathological specificity, PSMA has been a potential target for diagnosis and treatment of PCa (14, 15) .
New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells
Alternative splicing is a common phenomenon that can be observed in both benign and malignant tissues (16, 17) . A few PSMA splice variants have been found, including PSM', PSM-C, PSM-D, and PSM-E (18, 19) . PSM-E is an alternatively spliced variant we found previously that is different from other known variants (GenBank locus EF488811.2) (19) . Its cDNA includes 2653 nucleotides, has a 97 bp new exon inserted into the site between 379-380 of PSMA cDNA, and a 93 bp deletion located at the region of 2232-2324 nucleotides of PSMA cDNA (19) . Bioinformatics analysis showed that the PSM-E cDNA encodes a glycoprotein of 704 amino acids, with a possible signal peptide of 1-21aa, 150-250aa as a protease associated domain (PA domain), 355-549aa as a metallopeptidase domain, and 597-703aa as a TFR dimer domain. Though structurally similar, it may be functionally different from PSMA. We have found that PSM-E is specifically overexpressed in PCa, and has even higher tissue specificity and pathological specificity than PSMA (19) , but its biological function and its possible effect in PCa progression is still unknown. Our previous studies suggest it may be a candidate for a potent molecular marker for the measurement of PCa progression. So, in this study, using migration and invasiveness tests of PSM-E overexpression and interfering PCa cell models, we explored the effect of PSM-E and PSMA on the proliferation, invasiveness and migration of PCa cell lines in vitro. Our findings may contribute to revealing the potential role of PSM-E and PSMA in cancer progression, and may have some significance in understanding the biological role of PSM-E and PSMA.
Materials and methods
Cell lines. PCa cell lines LNCaP and PC-3 were obtained from American Type Culture Collection, and cultured in RPMI-1640 (Gibco-BRL, Invitrogen Co., Grand Island, NY, USA), 1 mM sodium pyruvate, 100 µ/ml penicillin G, 100 µg/ml streptomycin (Sigma, Ronkonkoma, NY, USA), 10% fetal bovine serum (FBS, Tianjin Hao Yang Biological Manufacture Co. Ltd, Beijing, China). Recombinant plasmid pMD18-T/PSM-E and pMD18-T/PSMA were constructed previously in our laboratory. shRNA expressing vector pSilencer 2.1-U6-neo was a product of Ambion Inc., Austin, USA.
Construction of PSMA/PSM-E eukaryotic expression vectors.
The PSM-E and PSMA cDNA was obtained, respectively, from recombinant plasmid pMD18-T/PSM-E and pMD18-T/ PSMA by common primers (19) . The forward primer was ATA GGATCC GAG ATG TGG AAT CTC CTT CAC, which contained the ribosome entry site and BamHⅠ restriction enzyme site; and the corresponding reverse primer was ATA CTCGAG TCC TCT TAG GCT ACT TCA CTC, corresponding to the 21-nucleotide near the 3' end and containing XhoⅠ restriction site. PCR amplification was carried out using high fidelity Platinum Taq DNA polymerase (Takara Biotechnology Co., Ltd, Dalian, China) in 50 µl total volume. PCR procedure was as follows: 94˚C for 5 min, cycle 1; 94˚C for 30 sec, 54.2˚C for 30 sec, 72˚C for 150 sec, cycle 2 through 35; then extended for 10 min at 72˚C. The expected fragment length of PSMA and PSM-E was 2279 and 2283, respectively. The products were recovered, restricted by BamHⅠ and XhoⅠ (Takara), ligated into pcDNA3.0 vector and transformed into The expression of PSMA and PSM-E protein in PC-3 cells. PC-3 cells were tranfected by identified recombinant pcDNA3.0/PSMA and pcDNA3.0/PSM-E, respectively, with Lipofectamine™ 2000 (Invitrogen Co., CA, USA). Vector negative control was PC-3 cells transfected by pcDNA3.0 plasmid. The positive recombinant cell clones were selected by G418 (Sigma), and the optimal concentration (500 µg/ml) was decided by the dose-response curve drawn previously. G418 resistant clones were expanded, collected, and the expression of target proteins was identified by RT-PCR, immunofluorescence and Western blotting. The PSMA specific forward primer used in RT-PCR identification was: 5'-GGA GGG ATG GTG TTT GAG C-3', and the corresponding reverse primer was: 5'-CTG CCT GGT AAC CCT AAT GG-3'. The expected product length of PSMA was 312 bp. The forward primer for PSM-E identification was: 5'-GCC AAC TGC AAG GTC TAA TG-3' , and the reverse primer: 5'-CCT GCT AAA TGT GGT ATC TGT G-3'. The expected product of PSM-E was 225 bp. PCR procedure was: 94˚C for 3 min, cycle 1; 94˚C for 30 sec, 55˚C for 30 sec, 72˚C for 30 sec, cycle 2 through 30; then extended for 5 min at 72˚C. β-actin was also amplified as an internal control. The forward primer for β-actin was: 5'-GCA TGG AGT CCT GTG GCA TCC-3', and the reverse primer: 5'-CAT TTG CGG TGG ACG ATG GAC-3'. The product length of β-actin was 319 bp and its PCR procedure was the same as that of PSMA and PSM-E. PCR products were identified by 1% agarose gel electrophoresis. The monoclonal antibody (YPSMA, ab19071; Abcam Inc., Cambridge, MA, USA) used in indirect immunofluorescence and Western blotting recognized 716-723 amino acid residues of the C terminus of PSMA. Cells were stained by FITC-labeled secondary goatanti-mouse antibody (Sigma) and counterstained by 0.02% Evan's blue. The antibody dilution ratio used in Western blotting was 1:1000 and in immunofluorescence 1:100. (Invitrogen) . The positive recombinant clones were selected by G418 (Sigma) for 14 days. The optimal concentration (700 µg/ml) was decided by the dose-response curve drawn previously. Stable G418 resistant clones of the four vectors (3 recombinant vectors and the negative control) were expanded, collected, and shRNA interference effect on PSMA and its splice variants was evaluated by RT-PCR and Western blotting. The recombinant vector sequencing primers were used first in RT-PCR to confirm transfection success. The forward primer was: 5'-GTT TTC CCA GTC ACG AC-3' , and the reverse primer was: 5'-GAG TTA GCT CAC TCA TTA GGC-3'. Expected product length was 546 bp. Then, after transfection confirmation, PSMA and its splice variants were amplified, with the consensus forward primer: 5'-TAC CAC ATT TAG CAG GAA CAG AAC-3' , and the consensus reverse primer: 5'-AAC CAT CTG GAT AGG ACT TCA CC-3'. The expected product length of PSMA series was 498 bp. β-actin served as an internal control (expected product length 318 bp). PCR procedure was: 94˚C for 5 min; 94˚C for 40 sec, 55˚C for 40 sec, 72˚C for 45 sec, 30 cycles; then extended for 3 min at 72˚C. PCR products were identified by 1.5% agarose gel electrophoresis. The monoclonal antibody (YPSMA, ab19071) used in Western blotting was product of Abcam, dilution ratio 1:1000, and detected by chemiluminescence. The resulting gels from RT-PCR and Western blotting were scanned and calculated by the software Image Pro Plus. The mRNA and protein relative quantity were calculated by the following formula: mRNA (or protein) relative quantity = target band gray scale/β-actin band gray scale. The inhibition rate calculation formula was: mRNA (or protein) inhibition rate = 1-(psiRNA mRNA relative quantity/pNC relative quantity).
Growth curve analysis. The identified stable transfected PC-3 and LNCaP cells (pcDNA3.0/PC-3, PSMA/PC-3, PSM-E/ PC-3 transfected PC-3 groups, 3 pSilencer 2.1-U6-neo-shRNA transfected LNCaP groups) and the negative control groups (non-transfected PC-3 cells and pSilencer 2.1-U6-neo-NC transfected LNCaP cells) were collected, digested by 0.25% trypsin and counted, then seeded onto 24-well plates (Corning Incorporated Costar) at the initial density of 2x10 4 cells/well. Transfected groups were continuously selected by 300 µg/ml G418. Cells were counted every 24 h for 5 days, each time counted 3 duplicate wells, using Typan blue staining to exclude dead cells. The growth curves were drawn for each group. Cell doubling time was calculated by the formula: T D =txlg2/lg(N t / N 0 ).
Cross-river test. The pcDNA3.0/PC-3, PSMA/PC-3, PSM-E/ PC-3 and PC-3 negative control cell groups, and p-shRNA3 transfected, p-NC transfected and LNCaP negative control cell groups were inoculated into 6-well plates (Corning Incorporated Costar). When the bottom was fully covered by a monolayer of cells, a straight line was scratched through the center of the well using a 20 µl tip. Flushing the stripped cells out of the line. The width of the scratched line was measured and the line was observed continuously until it was re-covered by adjacent cells. The time when the line was covered is reported as the migration time. For each group, the test was repeated 3 times to calculate the corresponding average scratching distance and migration time. The cell migration rate was calculated by: Migration velocity (µm/h) = scratching distance/migration time.
Transwell invasiveness test. The 24-well transwell chamber was a product of Corning Corporation. Fibronectin (10 µl) was applied on the under layer of the chamber membrane, and on the upper layer of the membrane, after washing the wells with PBS 3 times, 50 µl of Matrigel (dilution 1:50) was applied and allowed to solidify at 37˚C. BSA (50 µl) (concentration 10 g/l) was applied for blockage of binding sites and incubated at 37˚C for 30 min. After incubation, the remaining liquid was removed, and 200 µl of cell suspension (PC-3 cells and LNCaP cells) at the concentration of 1x10 5 cells/ml was added to the upper layer of the transwell chamber. RPMI-1640 medium (600 µl) supplemented with 1% FBS and 1% bovine serum albumin (BSA) was added to the underlayer of the chamber. The transwell chambers were incubated for 24 h at 37˚C, 5% CO 2 . After incubation, the culture medium was discarded, and the chamber was washed to remove cells that did not cross the membrane. The membrane was fixed in methanol for 5 min, and then the cells crossing the membrane were stained by Wright-Giemsa staining solution for 8-10 min and counted. For each group, 3 duplicate wells were counted. The invasiveness index was calculated by: invasiveness index = (invasive cell number of experimental group/ invasive cell number of control group) x100%.
Statistical analysis. SPSS11.5 was used for statistical analysis. Measurement data are shown as mean±SD. One-factor analysis of variance was used in data analysis between multiple groups. A value of P<0.05 was considered statistically significant.
Results
Construction of PSMA and PSM-E overexpression and interfering cell models. PSMA-pcDNA3.0 and PSM-E-pcDNA3.0 eukaryotic expression vectors were successfully constructed and confirmed by restriction and sequence analysis, transfected PC-3 cells, named respectively as PSMA/PC-3 and PSM-E/PC-3, to construct PSMA and PSME overexpression PC-3 cell models. Their expression in transfected PC-3 cells was identified by RT-PCR and immunofluorescence (Figs. 1 and 2). Three shRNAs were obtained and synthesized, and the corresponding pSilencer 2.1-U6-neo-shRNA expressing vectors, named respectively as p-shRNA1, p-shRNA2 and p-shRNA3 were constructed, identified by enzyme restriction, DNA sequencing, and their transfection success was verified by RT-PCR (data not shown), and their expression in LNCaP cells was confirmed by RT-PCR and Western blotting (Fig. 3) . The mRNA inhibition rate of p-shRNA1, 2, and 3 was 33.15%, 9.26% and 41.97%, respectively. The protein inhibition rate of p-shRNA1, 2, and 3 was 26.26%, 6.47% and 40.69%, respectively. The mRNA and protein inhibition rate of the negative control (p-NC group) was 10.1% and 7.97%, respectively. Therefore, p-shRNA1, and p-shRNA3 showed obvious inhibition effect at both mRNA and protein level (P<0.05 compared with negative control). So, p-shRNA3 was chosen for the following proliferation, migration and invasiveness tests in LNCaP cells as it showed the maximum inhibition effect.
Proliferation analysis of PSM-E/ PSMA overexpressed PC-3 cells and interfering LNCaP cells.
No significant change of proliferation was observed in PSMA/PC-3 overexpression cells and PSMA/PSM-E interfering LNCaP cells (P>0.05, Table Ⅰ), but in PSM-E/PC-3 cells, cell proliferation was significantly suppressed (P<0.05, Table Ⅰ ). There was no significant difference between PSMA/PC-3 cells and negative control/vector negative control cells (P>0.05, Fig. 4a ), indicating that expression of PSMA did not obviously change PC-3 cell proliferation. However, the cell doubling time of PSM-E/PC-3 cells was significantly longer compared with vector negative control and PC-3 negative control groups (P<0.05, Fig. 4a) , showing that PSM-E could suppress the proliferation of PC-3 PCa cells. Although compared with non-transfected LNCaP cells and p-NC group, no significant difference of proliferation was observed in p-shRNA3 group (P=0.12, Table Ⅰ, Fig. 4b ), it showed a trend of cell doubling time shortening. Therefore, PSM-E showed a certain effect of proliferation suppression of PCa cells, which may be covered by PSMA and other alternative spliced variants.
Migration analysis of PSM-E/PSMA overexpressed PC-3 cells and interfering LNCaP cells.
The migration speeds of PSM-E/PC-3, PSMA/PC-3, pcDNA3.0/PC-3 vector negative control and PC-3 negative control groups were 21.3±2.08, 21.0±3.61, 39.0±2.65 and 40.0±2.65 µm/h, respectively (Table Ⅱ) . Similar to that of PSMA, PSM-E showed the effect of migration suppression, and the migration speed was significantly slower compared with the vector negative control and non-transfected PC-3 negative control groups (P<0.01, Table Ⅱ, Fig. 5 ). However, there was no significant difference of the effect of migration suppression between PSM-E/PC-3 and PSMA/PC-3 (P>0.05). The migration speeds of p-shRNA3, p-NC and LNCaP cells were 40.6±2.44, 32.2±2.99, and 34.4±3.69 µm/h, respectively. The migration speed of p-shRNA3 transfected LNCaP cells was higher than that of p-NC and LNCaP control groups (P<0.05, Fig. 5 ), which was consistent with the results of PSM-E/PC-3 and PSMA/PC-3 cross-river tests, showing that both PSMA and its new alternatively spliced variant PSM-E had the activity of migration suppression of PCa cells.
Invasiveness analysis of PSM-E/PSMA overexpressed PC-3 cells and interfering LNCaP cells.
The results of transwell assay of PSM-E/PSMA overexpressed PC-3 cells showed that for PSMA/PC-3 group, the cells were the least invasive, and there was significant difference between PSMA/PC-3 group and vector negative control (P<0.01), and also between PSM-E/ PC-3 group and vector negative control (P<0.05, Table Ⅲ, Fig. 6a-d) . There was also significant difference of the invasive cell number between the PSM-E/PC-3 group and PSMA/ PC-3 (P<0.05, Table Ⅲ, Fig. 6 ), indicating that the effect of invasive suppression of PSMA was stronger than PSM-E. The invasiveness index of PSMA/PC-3 group was 45.10%, and the invasiveness index of PSM-E/PC-3 group was 80.83%. Accordingly, the Transwell assay results of PSM-E/PSMA interfering LNCaP cells showed that the invasive LNCaP cell number of p-shRNA3 group was significantly higher than the p-NC vector negative control group (P<0.01), and there was no The P-values of PC-3, PSMA/PC-3 and PSM-E/PC-3 groups were the P-value compared with the pcDNA3.0/PC-3 group (vector negative control), and P-values of LNCaP and p-shRNA3 group were the P-value compared with the p-NC group (vector negative control). a P<0.05 compared with vector negative control. The P-values of PC-3, PSMA/PC-3 and PSM-E/PC-3 groups were the P-value compared with the pcDNA3.0/PC-3 group (vector negative control), and P-values of LNCaP and p-shRNA3 group were the P-value compared with the p-NC group (vector negative control). significant difference between the p-NC group and the nontransfected LNCaP group (P>0.05, Table Ⅲ , Fig. 6e-f) . The invasiveness index of p-shRNA3 was 220.3%. The invasiveness analysis showed that PSM-E had the effect of invasive suppression, but the activity was weaker than PSMA.
Discussion
Alternative splicing is a fundamental mechanism in human differential gene expression, and can also be seen in cancer cells (16, 17) . Recent genome wide analysis of alternative splicing indicates that as much as 70% of human genes may have alternative spliced forms (17, 20, 21) . Changes in splice site selection and the production of splice variants have been observed in various types of cancer and may affect tumor progression and susceptibility to cancer. Four splice variants of PSMA have been reported as PSM' , PSM-C, PSM-D, and PSM-E (18) (19) (22) (23) . PSM' is located in the cytoplasm and produces a protein that lacks the intracellular and transmembrane domains of PSMA (18, 22, 23) . PSM-C generates a protein identical to PSM'. PSM-D has a new translation initiation start site in exon 1c, followed by 42 novel amino acids and the rest of the PSMA protein in frame (22) . There was evidence that the differential expression of PSMA and the above three alternatively spliced variants may be related to the progression of PCa (24) . PSM-E is a newly found splice variant, with a 97 bp of exon 1c insertion (similar to that of PSM-D) and a 93 bp deletion that was not seen in PSMA or in any of the known PSMA splice variants (19) . Our preliminary study showed its high tissue specificity and pathological specificity, but its role in PCa progression is still uncertain. Since the proliferation, invasiveness and migration ability of the malignant tumor cells in vitro could reflect, to a large extent, the process of tumor growth and progression in vivo, in this study, we constructed PSM-E and PSMA expressing cell clones, using PC-3 as the target cell line because PC-3 is a known PCa cell line that does not express PSMA or its splice variants, to explore the possible effect of PSM-E on the proliferation, invasiveness and migration of PCa cells. Accordingly, the PSMA and splice variants positive PCa cell line LNCaP was used to construct the shRNA interference cell model, to further verify the results of PSM-E/PSMA overexpressed PC-3 cells. Since some parts of the PSMA gene were homologous with other genes like transferrin receptor and M28 The P-values of PC-3, PSMA/PC-3 and PSM-E/PC-3 groups were P-value compared with the pcDNA3.0/PC-3 group (vector negative control), and P-values of LNCaP and p-shRNA3 group were the P-value compared with the p-NC group (vector negative control). family of co-catalytic aminopeptidases (3, 8, 25) , specificity and effectiveness were two capital considerations in siRNA design. Because PSMA, PSM-E and other splice variants are extremely homologous, it is hard to design siRNA that could distinguish PSM-E from PSMA and other splice variants and at the same time. Therefore, the siRNA used in this study was specific to PSMA and its splice variants.
The identification experiments showed that the PSMA and PSM-E gene had been successfully transfected into PC-3 cells, and can be successfully expressed at both the mRNA and protein level, as confirmed by RT-PCR and Western blot analysis. Three shRNA fragments were obtained based on the siRNA design principles of Elbashir et al (26) , recognization sites as 869 bp, 1589 bp, and 2149 bp, respectively. Their interference effect was evaluated using RT-PCR and Western blotting in LNCaP cells. After expression, all 3 shRNA showed inhibition effect at both mRNA and protein level. The mRNA inhibition rates of the constructed three 2.1-U6-neo-shRNA expression vectors (namely p-shRNA1,2,3) were 33.15%, 9.26% and 41.97%, respectively, and the protein inhibition rate was 26.26%, 6.47% and 40.69%, respectively, similar to other reported interfering RNAs (27) (28) . So 2.1-U6-neo-shRNA3 (namely p-shRNA3) was chosen in the following analysis, because it showed the maximum interference effect in expression of PSMA and its spliced variants.
To further evaluate the function of PSM-E/PSMA in the biological behavior of the PCa cells, proliferation analysis (tumor doubling time), invasiveness tests (transwell test) and migration tests (cross-river test) were carried out. In this study, there was no statistical difference of tumor doubling time between PSMA/PC-3 group and the vector negative control group, indicating that PSMA did not affect the cell growth significantly (P>0.05), whereas in PSM-E/PC-3 cells, cell proliferation was significantly suppressed (P<0.05, Table Ⅰ) , showing that PSM-E had the ability to suppress PCa cell proliferation. Although compared with non-transfected LNCaP cells and p-NC group, no significant difference of proliferation was observed in p-shRNA3 group, it also showed a trend of cell doubling time shortening. We presume that in PSMA and its spliced variants interfering LNCaP cells, the prolif- eration suppression effect may be covered up by PSMA and other alternative spliced variants. The mechanism of PSM-E suppressing cell proliferation will be further explored.
Invasiveness and metastasis are two major abilities of malignant tumors. Since PSM-E has somewhat different amino acid composition, what is the effect of PSM-E on cell migration and invasiveness of PCa cells? In our study, the cross-river tests showed that the migration speed of PSM-E/PC-3 group was similar to that of PSMA/PC-3 group (P>0.05), and both were significantly slower than the vector negative control group and PC-3 negative control (P<0.01, Table Ⅱ, Fig. 5 ), indicating that PSM-E, similar to PSMA, could suppress the migration of PCa cells. Accordingly, the migration speed of p-shRNA3 transfected LNCaP cells was higher than that of p-NC and LNCaP control groups (P<0.05, Fig. 5) , consistent with the results of PSM-E/PC-3 and PSMA/PC-3 cross-river tests, further confirming and showing that both PSMA and its alternatively spliced variant PSM-E had the activity of migration suppression of PCa cells.
The role of PSMA in tumor migration and invasiveness is still uncertain, and contradictory results exist. A recent study of Ghosh et al revealed that PSMA could suppress the PC-3 cell invasiveness (29) . In our study, similar phenomena were observed in PSMA/PC-3 transwell test (P<0.05 compared with the vector negative control), and PSM-E/PC-3 also showed the effect of invasive suppression (P<0.05, Table Ⅲ , Fig. 6a-d ), but the effect was weaker than PSMA (P<0.05). This was not an exceptional phenomenon in splice variants. It can be observed in other tumor-associated genes. The KAI1 gene is a PCa-suppressing gene that could suppress tumor metastasis, and the encoded protein of one of its splice variant (which lacked exon 7) showed weaker ability in suppressing tumor metastasis (30) . To our knowledge, this is the first report that such change can also be observed in PSMA and its splice variant, PSM-E. When PSMA and its splice variants were blocked, the invasiveness index of LNCaP increased dramatically (P<0.01), which further confirmed the invasiveness inhibition activity observed in PSM-E/PC-3 and PSMA/PC-3 cells.
It is of interest that the proliferation suppression effect of PSM-E was stronger than PSMA, whereas its invasiveness suppression effect was weaker than PSMA. Since PSM-E differ only a 97 bp insertion and a 93 bp deletion from PSMA, the mechanism behind cell biological behavior difference may lie in their structure difference. There was evidence that the activity of PSMA in suppressing tumor migration and invasiveness is due to its enzymatic activity, the NAALADase (29) . It was revealed that if the PSMA mutant without NAALADase activity was transfected into PC-3 cells, the cell invasiveness would be higher than that of the PC-3 cells transfected by PSMA with NAALADase activity, and if enzymatic inhibitor was applied in PSMA positive cells, the cell invasiveness would be enhanced (29) . The NAALADase activity can be affected by many factors such as the N terminal glycosylation and protein homodimer structure (31) . The exon 18 deletion of PSM-E would cause a shorter extracellular part of PSM-E protein, and there was evidence that lack of exon 18 may affect homodimer formation and cause the loss of NAALADase activity (32), thus, we believed that the weaker ability of PSM-E in suppressing PC-3 invasiveness and stronger effect on proliferation suppression may be due to this. Further study should be needed for direct evidence of its enzymatic activity, in order to know more about its function and possible use in the regulation of tumor progression and PCa treatment.
PSM-E is a newly found alternative splice variant of PSMA. In this study, it was revealed that PSM-E could affect the biological behavior of PCa cells. It is able to suppress PCa cell proliferation, migration and invasiveness. It had stronger effect of proliferation suppression than PSMA, similar effect of migration suppression but weaker effect of invasiveness suppression. The effect may be related to its TfR and NAALADase activity. To our knowledge, this is the first report on the effect of PSM-E on PCa cell proliferation, migration and invasiveness. Our findings may provide new insights into the relationships between the spliced variant construction and activity of PSMA and PSM-E, and may have important significance for the mechanism study of PSM-E contribution to cancer progression.
